Sep. 20, 2019	Results of Phase II Clinical Trials of New Drug Under Development
Jun. 05, 2019	Teijin Pharma Starts to Exclusive Sales of Transcranial Magnetic Stimulation Device in Japan
May. 29, 2019	Teijin Pharma Launches Revcovi®, Japan’s First Drug for ADA Deficiency
May. 14, 2019	Teijin and AMED Sign R&D Consignment Agreement to Develop Drugs for Frail
Mar. 26, 2019	Revcovi, Japan’s First Drug for ADA Deficiency, Receives Marketing Approval Obtainment of Manufacturing and Sales Approval for Etanercept Biosimilar, Anti-rheumatoid Arthritis Agent
Feb. 06, 2019	Administration of “JTR-161” Dental Pulp Stem Cells Product Starts in Clinical Trial in Japan

Page Top